"人工智能等技术对能源供给和能源结构提出了更高要求。中国在电力系统建设和能源转型方面的持续 投入，为相关技术的应用和拓展创造有利条件。"默根特勒说，世界经济论坛在相关研究中高度关注人 工智能与能源转型之间的关系，中国在低碳能源供给和技术应用结合方面的实践具有重要参考价值。 "扩大技术影响力需要更深层次的协作。"默根特勒说，在人工智能等技术快速演进的背景下，单一主体 难以独立完成从创新到规模化应用的全过程，中国通过企业之间、企业与科研机构之间，以及公共部门 与私营部门之间的合作，正推动技术成果更广泛落地。 默根特勒强调，当前一个共识越来越清晰：技术不能停留在概念层面，只有真正被应用到社会才能产生 价值。他表示，中国在相关领域拥有较强的实力和丰富的经验——一方面，新技术应用推进速度较快； 另一方面，新技术应用范围不断扩大，覆盖制造业、能源、医药等多个领域。"中国企业利用新技术重 塑业务流程、探索新的商业模式，积累了大量实践经验。"默根特勒说。 默根特勒表示，这种以应用为导向的创新路径，也在世界经济论坛的相关项目中得到体现。在论坛认定 的"全球灯塔工厂"和"人工智能应用之星"项目名单中，有相当一部分是中国企业，反映 ...

Core Viewpoint - The article emphasizes the integration of cultural heritage and economic development in Xuzhou, highlighting the city's historical significance and its ongoing transformation into a modern cultural and economic hub [14][15][24]. Group 1: Cultural Heritage and Economic Development - Xuzhou, known as Pengcheng, has a rich history of over 5,000 years and is recognized as a national historical and cultural city, with significant cultural symbols like the "Dafeng Song" [14][15]. - The city aims to promote high-quality development by intertwining cultural and economic growth, making the ancient "Dafeng Song" a contemporary symbol of progress [14][24]. - Historical figures such as Liu Bang, the founder of the Han Dynasty, and various cultural icons have shaped Xuzhou's identity, contributing to its cultural depth and economic resilience [15][16]. Group 2: Cultural and Ecological Restoration - Xuzhou has a long history of coal mining, which has led to significant ecological challenges; however, recent efforts have focused on ecological restoration, achieving a forest coverage rate of 31.60% and urban greening of 43.93% by 2025 [18]. - The city is actively working on urban renewal projects that blend cultural preservation with modern development, creating vibrant spaces that attract both locals and tourists [20][21]. Group 3: Tourism and Cultural Integration - Xuzhou is developing a diverse tourism product system that includes Han culture, red culture, and rural culture, aiming to convert cultural heritage into active tourism flow, with a reported 12.94% increase in visitor numbers during the 2025 National Day holiday [19]. - Innovative projects like the "Pengcheng Fenghua" live performance and digital initiatives are enhancing the cultural experience, driving significant economic benefits in the tourism sector [19][20]. Group 4: Industrial Transformation and Innovation - The city is undergoing a transformation by phasing out outdated industries and focusing on high-tech and strategic emerging industries, with the "343" innovation industry cluster projected to exceed 800 billion yuan by 2025 [22]. - Xuzhou is leveraging its educational institutions, with nearly 270,000 students contributing to the local talent pool, and has allocated 169 million yuan in various talent subsidies [22]. Group 5: Human-Centric Economic Development - The article highlights the importance of a people-centered approach in economic development, emphasizing the need for cultural values to resonate within the economic framework, thereby enhancing overall productivity and community well-being [17][24]. - Xuzhou promotes initiatives that enrich both the material and spiritual lives of its citizens, aiming for a balanced development that fosters cultural and economic prosperity [24].

陈茂波：香港金融和科技创新产业具发展潜力 中新社香港1月22日电 香港特区政府财政司司长陈茂波当地时间21日在瑞士达沃斯参加世界经济论坛 2026年年会活动时表示，香港在金融和科技创新产业上正不断探索和试验，具有相当大的发展潜力，值 得投资。 中新经纬版权所有，未经书面授权，任何单位及个人不得转载、摘编或以其它方式使用。 关注中新经纬微信公众号(微信搜索"中新经纬"或"jwview")，看更多精彩财经资讯。 编辑：熊思怡 广告等商务合作，请点击这里 本文为转载内容，授权事宜请联系原著作权人 来源：中国新闻网 陈茂波当日中午出席"2026达沃斯‧财新CEO午餐会"并发表主题演讲。他向与会嘉宾介绍了香港在过去 一两年所取得的稳健发展，以及未来在金融、贸易和创科三个主要增长引擎的发展愿景和布局。他指 出，人工智能和区块链等技术的突破正引发深刻的产业变革，驱动经济增长和转型，任何经济体都必须 拥抱这些发展；在"一国两制"下，香港在金融和科技创新产业上正不断探索和试验，加上与粤港澳大湾 区具备强大创科产业链的兄弟城市合作，具有相当大的发展潜力，值得投资。 他称，国际贸易正经历范式转移，发达国家需意识到部分发展中国家过去 ...

（记者 曾健辉） 每经AI快讯，新产业1月22日晚间发布公告称，深圳市新产业生物医学工程股份有限公司于近日收到1 项国家知识产权局、2项俄罗斯联邦知识产权局颁发的《发明专利证书》。专利名称分别为"全血样本中 待测物的免疫学检测方法、磁性微球及磁性微球-蛋白复合物中国专利号""试剂组合以及免离心的全血 中目标免疫抑制剂的检测方法"等。 每经头条（nbdtoutiao）——特朗普强要格陵兰岛，丹麦一养老基金率先清仓美债，美国资产全线下 跌！欧洲手握"金融核按钮"，双方会"鱼死网破"吗？专家解读→ ...

据天眼查APP显示，深圳市新产业生物医学工程股份有限公司成立于1995年12月15日，注册资本 78571.8785万人民币。（数据宝） 新产业1月22日大宗交易平台出现一笔成交，成交量961.78万股，成交金额5.27亿元，大宗交易成交价为 54.77元，相对今日收盘价折价3.10%。该笔交易的买方营业部为机构专用，卖方营业部为华泰证券股份 有限公司成都蜀金路证券营业部。 进一步统计，近3个月内该股累计发生10笔大宗交易，合计成交金额为9.01亿元。 证券时报·数据宝统计显示，新产业今日收盘价为56.52元，下跌0.51%，日换手率为0.60%，成交额为 2.34亿元，全天主力资金净流入2687.24万元，近5日该股累计下跌2.84%，近5日资金合计净流入1.06亿 元。 两融数据显示，该股最新融资余额为9.04亿元，近5日增加3149.03万元，增幅为3.61%。 1月22日新产业大宗交易一览 | 成交量 | 成交金额 | 成交价格 | 相对当日收盘折溢 | 买方营 | 卖方营业部 | | --- | --- | --- | --- | --- | --- | | （万股） | （万元） | （元） | ...

Core Viewpoint - The company has received a medical device registration certificate for its Immunoglobulin G (IgG) assay kit, which is expected to positively impact its development but will not significantly affect recent production or performance [1] Group 1: Product Development - The product is an IgG assay kit using latex immunoturbidimetry, designed for the quantitative measurement of IgG levels in human urine [1] - This new product enriches the company's biochemical testing product line in the "renal function" category [1] Group 2: Market Impact - The approval of the medical device registration certificate is anticipated to have a positive influence on the company's growth [1] - However, it is noted that there will be no major impact on the company's recent operations and financial performance [1]

证券代码：300832 证券简称：新产业 公告编号：2026-005 深圳市新产业生物医学工程股份有限公司 关于获得医疗器械注册证的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 近日，深圳市新产业生物医学工程股份有限公司（以下简称"公司"）收到 了广东省药品监督管理局颁发的 1 项《医疗器械注册证》。具体情况如下： 由于肾小球的滤过膜和肾小管的重吸收作用可以阻止大部分蛋白质进入尿 液，所以在正常情况下尿液中的 IgG 含量极少。当它们出现或升高，常提示肾小 球滤过膜受损，是辅助诊断肾小球肾炎、糖尿病肾病等疾病的重要指标。尿 IgG 升高常反映肾小球毛细血管壁广泛损伤和出现肾病范围内蛋白尿的原发性肾小 球疾病，如膜性肾病、局灶节段性肾小球硬化和膜性增生性肾小球肾炎的临床进 展和慢性肾衰竭的进展，并与小管间质损伤相关。此外，尿 IgG 对糖尿病肾病的 发病具有一定的预测作用。系统性红斑狼疮、类风湿性关节炎等自身免疫性疾病 患者中可见尿 IgG 水平升高。 1 二、对公司的影响及风险提示 截至目前，公司已先后取得 77 项生化试剂《医疗器械注册证》（共 11 ...

证券代码：300832 证券简称：新产业 公告编号：2026-006 深圳市新产业生物医学工程股份有限公司 关于公司获得发明专利证书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 深圳市新产业生物医学工程股份有限公司（以下简称"公司"）于近日收到 1项国家知识产权局、2项俄罗斯联邦知识产权局颁发的《发明专利证书》，现将 本次取得的发明专利具体情况公告如下： 1、 发明名称：全血样本中待测物的免疫学检测方法、磁性微球及磁性微球-蛋白复合物 中国专利号：ZL202411999352.2 专利权人：深圳市新产业生物医学工程股份有限公司 发明人：张云、钟亮、张卓玲、闫璐璐、卢东林 专利权人：深圳市新产业生物医学工程股份有限公司 专利申请日：2024年12月31日 发明人：饶捷、李婷华、张云、罗春、郑文迪、徐红 授权公告日：2026年01月09日 专利申请日：2024年12月25日 上述专利保护技术为公司自主研发，本发明涉及一种应用于急诊平台的全血 检测方法。通过采用表面含甲基丙烯酸酯的磁性微球为固相载体，并以DMTMM 交联剂进行特异性蛋白的偶联，有效解决了磁 ...

中新网武汉1月22日电 湖北省"51020"先进制造业集群产业生态之医工交叉产业对接活动22日在武汉举 行，湖北省医工交叉融合创新产业联盟正式揭牌成立，31项医工交叉融合创新项目及产业化项目达成合 作，意向投资总额约12亿元，涉及医工交叉产业全链条合作，涵盖产学研医融全生态协同。 湖北省医工交叉融合创新产业联盟，是在湖北省经信厅、湖北省卫健委、湖北省药监局等部门指导下组 建的省级医工融合创新转化平台。该联盟汇聚医疗机构、高校院所、投融资机构、医药龙头及专业服务 机构等多家核心单位，构建起"临床需求—技术研发—中试熟化—资本赋能—产业落地"的全链条创新生 态体系。 现场，湖北省2025年医工交叉揭榜挂帅十大创新项目正式发布。湖北省经信厅将对揭榜项目给予最高 500万元资金扶持，推动创新链、产业链、资金链深度融合，加速以生物医药为核心的大健康产业高质 量发展。(完) （文章来源：中国新闻网） 湖北省医工交叉融合创新产业联盟理事长马丁表示，联盟将动员平台机构和医药企业力量，聚焦科创成 果转化早介入、早对接、早融合，在概念验证、中试熟化、临床研究、法规认证、产业化等各环节进行 孵化，培育更多医疗创新型科技企业，不断壮 ...

Summary of China Healthcare Industry Conference Call Industry Overview - **Industry**: China Healthcare Industry - **Report Date**: January 21, 2026 - **Sentiment**: Cautiously optimistic outlook for 2026 regarding hospital capital expenditures and market dynamics [1][2] Key Insights Capital Expenditure Trends - **Stable to Moderate Growth**: Hospital capital expenditures are expected to remain stable with moderate growth in 2026 [2] - **Survey Results**: 59% of surveyed hospital managers anticipate capital expenditure growth in 2026, up from 43% in late 2024, but still below 85% in late 2023 [3] - **Projected Growth Rate**: Expected capital expenditure growth of 4.7% in 2026, compared to 3.0% growth anticipated for 2025 [3] - **Actual Growth Expectations**: Respondents expect actual capital expenditure growth of 5.8% for 2025, indicating limited visibility on actual demand [3] Key Drivers of Expenditure - **Primary Drivers**: 1. Hospital Surplus (69%) 2. Patient Demand (50%) 3. Local Fiscal Budgets (44%) [3] - **Service Volume Constraints**: Factors such as Diagnosis-Related Group (DRG) payment limits and medical insurance settlements are seen as major constraints on service volume [3] Equipment and Technology Focus - **Investment Priorities**: Hospitals are prioritizing investments in AI, endoscopy, and imaging equipment, with a focus on surgical and flexible endoscopes, followed by CT and ultrasound [3] - **Weak Demand**: In vitro diagnostics are expected to remain weak [3] Company-Specific Insights Beneficiaries of Capital Expenditure Growth - **Mindray Medical (300760.SZ)**: Expected to benefit from a stable capital expenditure environment, with anticipated single-digit revenue growth in 2026. The company is expected to maintain a 16% share of planned capital expenditures [4][10] - **United Imaging (688271.SS)**: Anticipated to benefit from strong demand in high-end imaging, with projected revenue growth of approximately 21% in 2026 [4][11] - **New Industries (300832.SZ)**: Expected to face continued pricing pressure in in vitro diagnostics but may achieve above-industry growth due to healthy demand for chemical luminescence analyzers [4][12] - **Huatai Medical (688617.SS)**: Positioned to capitalize on the growing adoption of pulse field ablation technology, with projected revenue growth of 30% in 2026 [4][13] - **Guichuang Tongqiao (2190.HK)**: Expected to see revenue growth of around 30% driven by increased demand for neurointerventional and peripheral interventional procedures [4][15] Challenges for Global Players - **GE Healthcare**: Faces mixed impacts from increased capital expenditure and growing preference for local brands, which may offset some growth [4][16] - **Siemens Healthineers (SHL)**: Cautious outlook due to slow recovery in utilization rates and increased pricing pressure from procurement policies [4][17] - **Philips (PHIA)**: Similar cautious outlook with potential declines in market share for CT and ultrasound equipment [4][18] - **Olympus (7733.T)**: Expected to face challenges in maintaining market share in the digestive endoscopy market [4][19] - **Hologic (6869.T)**: Anticipated slowdown in clinical testing volumes and potential market share decline in hematology [4][20] Additional Observations - **Market Dynamics**: The report highlights a complex landscape for global medical technology companies in China, with both opportunities and pressures from local competition and procurement policies [4][16][17][18][19][20] - **Emerging Trends**: The shift towards local brands and the impact of procurement policies are significant trends that may reshape the competitive landscape in the healthcare sector [4][16][17][18][19][20]